Lyon, France, January 10th, 2016
OREGA Biotech announces Licensing Agreement with Innate Pharma
OREGA Biotech today announces that it has entered into an exclusive licensing agreement with Innate Pharma by which OREGA grants Innate full worldwide rights to its program of first-in-class anti-CD39 immune checkpoint inhibitors. This license agreement arose from a fruitful research collaboration between the two companies initiated in 2014. Under the terms of the agreement, OREGA Biotech will receive undisclosed upfront payment, milestone payments for preclinical, clinical and regulatory achievements as well as royalties on net sales.
For more information, read the press release.